Skip to main content

Early Psychosis clinical trials at UCSD

1 in progress, 0 open to eligible people

Showing trials for
  • Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

    Sorry, not yet accepting patients

    This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.

Last updated: